Tissue Genix provides an AI‑enabled platform that translates experimental designs into reproducible 3D human tissue constructs printed directly into standard multiwell plates.
Funding
Funding not disclosed
Founders
Product
Problem
Preclinical drug development often relies on animal models and low‑throughput 2D cell assays, which can produce data that poorly predict human responses and limit regulatory acceptance of new approach methodologies (NAMs).
Solution
Tissue Genix offers an AI‑enabled platform that converts experimental designs into reproducible 3D human tissue constructs printed directly into standard multiwell plates. The workflow automates quantitative phenotyping and generates standardized reports, allowing researchers to capture functional readouts that are more predictive of human biology. By integrating in‑vitro bioprinted tissues with computational models, the system supports regulator‑driven moves toward human‑relevant preclinical testing and streamlines adoption of NAMs in everyday laboratory workflows.
Target Audience
Primary customers are pharmaceutical and biotechnology R&D teams, contract research organizations, and regulatory science groups seeking human‑relevant, high‑throughput preclinical testing solutions.
Features
- AI‑driven design translation that maps experimental protocols to printable 3D tissue geometries
- High‑precision bioprinting of human tissue constructs compatible with standard multiwell plate formats
- Automated quantitative phenotyping pipelines that extract functional metrics from the printed tissues
- Generation of standardized, regulator‑ready reports to facilitate data sharing and compliance
- Integration layer for coupling in‑vitro results with computational models to enhance predictive power